Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.53 |
| ▸ | CCR6 | P51684 | 2/20 | 0.47 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.46 |
| ▸ | GCK | P35557 | 1/20 | 0.45 |
| ▸ | CCNK | O75909 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10114634 | 0.88 | NPY5R (0.72) | EPHX2NPY5RTRPV1CCR6PANK3 | |
| SCHEMBL13840454 | 0.87 | NPY5R (0.54) | EPHX2NPY5RTRPV1CCR6CCNK | |
| SCHEMBL14424799 | 0.85 | NPY5R (0.75) | EPHX2NPY5RCCR6GCKPTGS1 | |
| SCHEMBL10114602 | 0.85 | NPY5R (0.75) | EPHX2NPY5RCCR6GCKPTGS1 | |
| SCHEMBL10114622 | 0.85 | EPHX2 (0.57) | EPHX2TRPV1CNR1CNR2 | |
| SCHEMBL10116019 | 0.81 | EPHX2 (0.46) | EPHX2TRPV1 | |
| SCHEMBL10116041 | 0.79 | EPHX2 (0.57) | EPHX2TRPV1 | |
| SCHEMBL10116064 | 0.78 | TEAD1 (0.49) | EPHX2 | |
| SCHEMBL10116168 | 0.78 | EPHX2 (0.37) | EPHX2TRPV1 | |
| SCHEMBL10115869 | 0.77 | CNR2 (0.54) | EPHX2TRPV1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
| US-20070015762-A1 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015762-A1 | NPY Y5 antagonist | NPY5R, NPY1R, NPY2R | EPHX2 2158/4885NPY5R 1/4885TRPV1 774/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | EPHX2 2527/4885NPY5R 1/4885TRPV1 534/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | EPHX2 2306/4885NPY5R 1/4885TRPV1 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.